Glycosylated specificity exchanger

Abstract

The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.

1 . An isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to a blood group antigen. 
     
     
         2 . The isolated glycoconjugate peptide of  claim 1 , wherein said glycoconjugate peptide is linear. 
     
     
         3 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is blood group antigen A. 
     
     
         4 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is blood group antigen B. 
     
     
         5 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is blood group antigen RhD. 
     
     
         6 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is synthetically conjugated to said HIV gp120 binding fragment of CD4 by attachment at one amino acid. 
     
     
         7 . The isolated glycoconjugate peptide of  claim 6 , wherein said blood group antigen is synthetically conjugated to a hydroxylated amino acid. 
     
     
         8 . The isolated glycoconjugate peptide of  claim 6 , wherein said blood group antigen is synthetically conjugated by an NH 2 -linkage. 
     
     
         9 . The isolated glycoconjugate peptide of  claim 6 , wherein said blood group antigen is synthetically conjugated to the N-terminal end of HIV gp120 binding fragment of CD4. 
     
     
         10 . The isolated glycoconjugate peptide of  claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 200 amino acids in length. 
     
     
         11 . The isolated glycoconjugate peptide of  claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 150 amino acids in length. 
     
     
         12 . The isolated glycoconjugate peptide of  claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 100 amino acids in length. 
     
     
         13 . The isolated glycoconjugate peptide of  claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 50 amino acids in length. 
     
     
         14 . The isolated glycoconjugate peptide of  claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 25 amino acids in length. 
     
     
         15 . The isolated glycoconjugate peptide of  claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than or equal to 15 amino acids in length. 
     
     
         16 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is synthetically conjugated to a hydroxylated amino acid. 
     
     
         17 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is synthetically conjugated by an NH 2 -linkage. 
     
     
         18 . The isolated glycoconjugate peptide of  claim 1 , wherein said blood group antigen is synthetically conjugated to the N-terminal end of said HIV gp120 binding fragment of CD4. 
     
     
         19 . A method of ameliorating HIV proliferation in a subject comprising:
 identifying a subject infected with HIV; and   providing an isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to a blood group antigen to said subject.   
     
     
         20 . A method of ameliorating HIV proliferation in a subject comprising:
 identifying a subject infected with HIV; and   providing an isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to gal a (1,3) gal β to said subject.